Recursion
Founded Year
2013Stage
Corporate Minority - P2P | IPOTotal Raised
$509.79MMarket Cap
1.59BStock Price
8.38Revenue
$0000About Recursion
Recursion (NASDAQ: RXRX) is a clinical-stage biotechnology company combining experimental biology and automation with artificial intelligence in a parallel system to efficiently discover potential drugs for diverse indications, including genetic disease, inflammation, immunology, and infectious disease. The company was founded in 2013 and is based in Salt Lake City, Utah.
Missing: Recursion's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Recursion's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing Recursion
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Recursion in 13 CB Insights research briefs, most recently on Mar 16, 2022.
Feb 16, 2022
The 130+ AI startups reinventing healthcare
Apr 7, 2021 report
AI 100: The Artificial Intelligence Startups Redefining IndustriesApr 7, 2021 report
AI 100: The Artificial Intelligence Startups Redefining Industries
Expert Collections containing Recursion
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Recursion is included in 8 Expert Collections, including Digital Health.
Digital Health
21,956 items
Startups recreating how healthcare is delivered
AI 100
299 items
Conference Exhibitors
5,501 items
HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare
Artificial Intelligence
9,442 items
This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.
Digital Health 150
300 items
2019's cohort of the most promising digital health startups transforming the healthcare industry
Cancer
3,605 items
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Recursion Patents
Recursion has filed 1 patent.
The 3 most popular patent topics include:
- Biotechnology
- Genetics
- Molecular biology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
7/20/2020 | 11/15/2022 | Drug discovery, Fault tolerance, Medicinal chemistry, Parallel computing, Cheminformatics | Grant |
Application Date | 7/20/2020 |
|---|---|
Grant Date | 11/15/2022 |
Title | |
Related Topics | Drug discovery, Fault tolerance, Medicinal chemistry, Parallel computing, Cheminformatics |
Status | Grant |
Latest Recursion News
Nov 9, 2022
Nasdaq By Zacks Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 2.78%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.35 per share when it actually produced a loss of $0.38, delivering a surprise of -8.57%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. AD AD Recursion Pharmaceuticals, which belongs to the Zacks Medical - Drugs industry, posted revenues of $13.16 million for the quarter ended September 2022, surpassing the Zacks Consensus Estimate by 104.57%. This compares to year-ago revenues of $2.53 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Recursion Web Traffic
Recursion Rank
Recursion Frequently Asked Questions (FAQ)
When was Recursion founded?
Recursion was founded in 2013.
Where is Recursion's headquarters?
Recursion's headquarters is located at 41 S Rio Grande St, Salt Lake City.
What is Recursion's latest funding round?
Recursion's latest funding round is Corporate Minority - P2P.
How much did Recursion raise?
Recursion raised a total of $509.79M.
Who are the investors of Recursion?
Investors of Recursion include Baillie Gifford & Co., Mubadala Investment Company, Laurion Capital Management, Platinum Investment Management, Kinnevik and 29 more.
Who are Recursion's competitors?
Competitors of Recursion include Insilico Medicine, Cyclica, nference, METiS Therapeutics, BenevolentAI, Terray Therapeutics, Exscientia, XtalPi, BioSymetrics, BioMap and 17 more.
Compare Recursion to Competitors
insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients.
Atomwise uses deep learning neural networks to help discover new medicines. Atomwise achieves results for new drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise predicts drug candidates for pharmaceutical companies, start-ups, and research institutions. It is currently using computational drug design to design drugs against COVID.
Insilico Medicine develops a range of Generative Adversarial Networks (GANs) and reinforcement learning approaches to identify protein targets, generate molecular structures with specified properties, and generate synthetic data. The company provides pharmaceutical and biotechnology companies with artificial intelligence solutions for research and development. It was founded in 2014 and is based in Hong Kong.
Cyclica offers artificial intelligence (AI) and computational biophysics based drug discovery process. Its structure-based and artificial intelligence (AI) augmented drug discovery platform includes Ligand Design for multi-targeted and multi-objective drug design, and Ligand Express for off-target profiling, systems biology linkages, and structural pharmacogenomic insights. The company was founded in 2013 and is based in Toronto, Canada.
Healx is an AI-powered and patient-inspired technology company, accelerating the discovery and development of rare disease treatments. Its AI drug discovery platform leverages public and proprietary biomedical data and features a knowledge graph for rare diseases.
Aria Pharmaceuticals is a preclinical-stage pharmaceutical company that discovers and develops novel small molecule therapies for complex and hard-to-treat diseases
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.